EFIC-Grünenthal Grant supports young scientists
Apply for 2012 at www.e-g-g.info

Aachen, Germany, 29 March 2012. Young scientists from across Europe are invited to apply for the EFIC-Grünenthal Grant (E-G-G) 2012, one of the most highly regarded pain research grants worldwide. Provided by the European Federation of IASP® Chapters (EFIC®) and the pharmaceutical company and pain expert Grünenthal GmbH, this grant supports young scientists early in their career in conducting innovative and exploratory clinical pain research projects.

Grüenthal donates a total of € 200,000 for the biennial grant, which is shared between the awarded scientists and is intended to support them early in their career. The individual grants are valued at up to € 40,000 per project for a duration of up to two years. The decision of the awards is made independently by the EFIC® Committee on Research.

Interested young scientists can submit their research projects online at: www.e-g-g.info until the end of 2012.

About EFIC®
The European Federation of IASP® Chapters (EFIC®) is a multidisciplinary professional organisation in the field of pain research and medicine, consisting of the 35 so-called chapters of the International Association of the Study of Pain (IASP®), which are the IASP® approved official pain societies in each country. Established in 1993, EFIC’s constituent chapters represent pain societies from 35 European countries and close to 20,000 scientists, physicians, nurses, physiotherapists, psychologists and other healthcare professionals across Europe, who are involved in pain management and pain research.

About Grüenthal

The Grüenthal Group is an independent, family-owned international research based pharmaceutical company headquartered in Aachen, Germany. Building on its unique position in pain, its objective is to become the most patient-centric company to be a leader in therapy innovation. Grüenthal is
one of the last five research-oriented pharmaceutical corporations with headquarters based in Germany which sustainably invests in research and development. These investments amounted to about 25% of revenues in 2011. Grünenthal’s research and development strategy concentrates on select fields of therapy and state-of-the-art technologies. We focus on the intensive search for new ways to treat pain better, more effectively and with fewer side-effects than before. Altogether, the Grünenthal Group has affiliates in 26 countries worldwide. Grünenthal products are sold in more than 155 countries and approx. 4,500 employees are working for the Grünenthal Group worldwide. In 2011, Grünenthal reached estimated revenues of 947 Mio €. More information: www.grunenthal.com.